Dale Bixby

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/902431/publications.pdf

Version: 2024-02-01

26	1,471	687335 13	642715 23
papers	citations	h-index	g-index

26	26	26	2509
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 926-957.	4.9	451
2	HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature Medicine, 2010, 16, 446-451.	30.7	279
3	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 16-27.	4.9	170
4	Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology American Society of Hematology Education Program, 2009, 2009, 461-476.	2.5	153
5	HIV-1 Utilizes the CXCR4 Chemokine Receptor to Infect Multipotent Hematopoietic Stem and Progenitor Cells. Cell Host and Microbe, 2011, 9, 223-234.	11.0	103
6	CD133+ Hematopoietic Progenitor Cells Harbor HIV Genomes in a Subset of Optimally Treated People With Long-Term Viral Suppression. Journal of Infectious Diseases, 2013, 207, 1807-1816.	4.0	51
7	CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo. PLoS Pathogens, 2017, 13, e1006509.	4.7	42
8	FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplantation, 2016, 51, 511-520.	2.4	40
9	Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/Lymphoma. Journal of Molecular Diagnostics, 2016, 18, 595-603.	2.8	36
10	Hematopoietic Stem and Progenitor Cells Are a Distinct HIV Reservoir that Contributes to Persistent Viremia in Suppressed Patients. Cell Reports, 2018, 25, 3759-3773.e9.	6.4	33
11	The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis. Cell Cycle, 2008, 7, 971-979.	2.6	25
12	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. British Journal of Haematology, 2019, 185, 595-598.	2.5	19
13	Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. Bone Marrow Transplantation, 2019, 54, 1518-1520.	2.4	18
14	Fibroblast Growth Factor 23â€“Induced Hypophosphatemia in Acute Leukemia. Journal of the Endocrine Society, 2018, 2, 437-443.	0.2	14
15	Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia. Supportive Care in Cancer, 2017, 25, 541-547.	2.2	9
16	Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. Blood Advances, 2019, 3, 3333-3336.	5.2	8
17	Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. Journal of Oncology Pharmacy Practice, 2016, 22, 811-815.	0.9	5
18	Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase. Leukemia and Lymphoma, 2016, 57, 1002-1014.	1.3	5

#	Article	IF	Citations
19	A diagnosis of discernment: Identifying a novel ATRX mutation in myelodysplastic syndrome with acquired Î±-thalassemia. Cancer Genetics, 2019, 231-232, 36-40.	0.4	3
20	Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalitiesâ€"AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 24-30.	0.4	3
21	Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study. Journal of Oncology Pharmacy Practice, 2022, 28, 1315-1325.	0.9	2
22	The Challenge of t(6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult. Journal of Leukemia (Los Angeles, Calif), 2014, 02, .	0.1	1
23	Identification of variant APL translocations PRKAR1A-RARÎ± and ZBTB16-RARÎ± (PLZF-RARÎ±) through the MI-ONCOSEQ platform. Cancer Genetics, 2021, 258-259, 57-60.	0.4	1
24	253. Febrile Neutropenia Antibiotic De-escalation Study in Acute Myeloid Leukemia Patients With Prolonged Neutropenia. Open Forum Infectious Diseases, 2018, 5, S107-S107.	0.9	0
25	Prevalence of bloodstream infections in neutropenic patients with bacteriuria. Infection Control and Hospital Epidemiology, 2019, 40, 955-956.	1.8	0
26	Hematopoietic Stem and Progenitor Cells (HSPCs). Methods in Molecular Biology, 2022, 2407, 115-154.	0.9	0